News | December 25, 2023
Lyndra Therapeutics raises US$101 million in Series E funding
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
WINLEVI works differently from any other topical acne treatment
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Subscribe To Our Newsletter & Stay Updated
